GPX2 and non-small cell lung carcinoma: Additionally, α-Hederin treatment inhibited GSH synthesis and disrupted the GSH redox system by downregulating the expression of glutathione peroxidase 2 (GPX2) and glutathione synthetase (GSS), thereby inducing ferroptosis at a low-toxicity dose and enhancing cisplatin chemotherapy resistance in NSCLC cells [93].